EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study

Qiu-Yi Pan iD, Ya-Xue Wang iD, Xue-Ying Tang, Zan Hou, Bai-Qiang Dong, Qi-Wen Li iD, Bao-Qing Chen, Shou-Min Bai iD, Chen-Fei Wu, Ming Chen

PLOS Medicine · 05.08.2026 · 23 (8) · e1004817

DOI: 10.1371/journal.pmed.1004817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 05.08.2026. Verfasst von Qiu-Yi Pan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Collaborative Innovation Cen…. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Lung Injury, Pyridones, Radiation Injuries. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, the Science and Technology Projects in Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The cost-effective treatment strategy for radiation-induced lung injury (RILI) remains unclear. Our recent phase II randomized clinical trial has proved pirfenidone to be safe and effective for grade 2 or 3 RILI. Here, we aim to assess the cost-effectiveness of pirfenidone plus glucocorticoids versus glucocorticoids alone for the treatment of grade 2 or 3 RILI. Methods and findings We constructed a Markov model based on the individual-level data from our trial (NCT03902509) to evaluate the cost-effectiveness of pirfenidone plus glucocorticoids. Outcomes were simulated in a 4-week cycle over a 24-week time horizon to model patients who had acute pulmonary exacerbation or RILI progression. Costs and utilities were discounted at 3% annually. Health outcomes were measured using incremental cost-effectiveness ratio (ICER), representing incremental costs per quality-adjusted life year (QALY) gained between the two treatment groups. One-way and probabilistic sensitivity analyses were conducted to evaluate the model uncertainties. The simulated RILI pattern in the Markov model closely matched the pattern in the trial cohort, indicating that the model accurately described the disease process of RILI. Compared with glucocorticoids alone, pirfenidone plus glucocorticoids yielded an additional 0.028 QALYs at an incremental cost of $590, with an ICER of $20,956 per QALY gained. The ICER was considerably below the commonly accepted willingness-to-pay (WTP) threshold of $100,000 per QALY. In one-way sensitivity analyses, the variables with the greatest influence on the ICER included the acute pulmonary exacerbation-free survival and the probability of non-response among patients with grade 2 or 3 RILI in glucocorticoid group. Moreover, the probabilistic sensitivity analysis demonstrated that pirfenidone plus glucocorticoids had a 99.98% probability of being cost-effective at the WTP threshold of $100,000/QALY. Limitations include the phase II trial data with limited sample size and follow-up. An ongoing phase III trial will provide further evidence.

Conclusions

For grade 2 or 3 RILI, pirfenidone plus glucocorticoids is cost-effective compared with glucocorticoids alone. This strategy offers a practical and evidence-based option for RILI clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalLung InjuryPyridonesRadiation InjuriesFemaleHumansMaleCost-Effectiveness AnalysisGlucocorticoidsMarkov ChainsQuality-Adjusted Life YearsRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Substanzen

Anti-Inflammatory Agents, Non-SteroidalGlucocorticoidspirfenidonePyridones

Autor:innen und Institutionen

  • Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Collaborative Innovation Center of Cancer Medicine, Guangzhou, P. R. China.
  • United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co, Ltd, Guangzhou, P. R. China.
  • Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, P. R. China.
  • Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of…

ORCID-Profile: Qiu-Yi Pan, Ya-Xue Wang, Qi-Wen Li, Shou-Min Bai

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Natural Science Foundation of China
  • the Science and Technology Projects in Guangzhou
  • China Postdoctoral Science Foundation

Zitieren

APA

Pan, Q. Y., Wang, Y. X., Tang, X. Y., Hou, Z., Dong, B. Q., Li, Q. W., Chen, B. Q., Bai, S. M., Wu, C. F., & Chen, M. (2026). Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study. PLOS Medicine, 23(8), e1004817. https://doi.org/10.1371/journal.pmed.1004817

Vancouver

Pan QY, Wang YX, Tang XY, Hou Z, Dong BQ, Li QW, et al. Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study. PLOS Medicine. 2026;23(8):e1004817. doi:10.1371/journal.pmed.1004817

BibTeX
@article{Pan2026,
  author = {Pan, Qiu-Yi and Wang, Ya-Xue and Tang, Xue-Ying and Hou, Zan and Dong, Bai-Qiang and Li, Qi-Wen and Chen, Bao-Qing and Bai, Shou-Min and Wu, Chen-Fei and Chen, Ming},
  title = {Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {8},
  pages = {e1004817},
  doi = {10.1371/journal.pmed.1004817}
}
Kostenlos starten →